Common Heart Drug Recalled In 22 Countries For Possible Cancer Link

(CNN) — A common drug used to control blood pressure and help prevent heart failure is being recalled in 22 countries because it contains a chemical that poses a potential cancer risk. Valsartan is off-patent and is used as a component of other generic medicines. Novartis, the company that originally developed the drug, said Sandoz valsartan and valsartan/HCT film-coated tablets are being recalled since they “do not meet our high quality standards.” Pharmacies in the UK are advised to recall valsartan batches containing medicines made by Dexcel Pharma Ltd and Accord Healthcare. The recall involves about 2,300 batches that were sent to Germany, Norway, Finland, Sweden, Hungary, the Netherlands, Austria, Ireland, Bulgaria, Italy, Spain, Portugal, Belgium, France, Poland, Croatia, Lithuania, Greece, Canada, Bosnia and Herzegovina, Bahrain and Malta. Novartis spokesman Eric Althoff said that products sold in the United States are not affected by this recall. The US Food and Drug Administration says it is looking to see whether it “has any information to share at this time” and directed questions to the manufacturer, as it is “the best source of information about their product.” The problem was discovered during tests of batches of valsartan’s active pharmaceutical ingredient (API), as those from an external supplier contained an impurity. The European Medicines Agency reviewed medicines from the supplier, Zhejiang Huahai Pharmaceuti...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Valsartan Source Type: news

Related Links:

Study results suggest that PDE-5 inhibitors could have a role in treating cancer, heart failure, neurodegenerative diseases, circulatory disorders and even infectious diseases, but the road to approval for new indications may not be smooth.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Conclusion Evidence of clinical benefit of most available apps is very limited. Design features that enhance usability and maximise efficacy were identified. A provisional 'first-pass' evaluation framework is proposed that can help decide which apps should be endorsed by government agencies following more detailed technical assessments and which could then be recommended with confidence by clinicians to their patients.What is known about the topic? Smartphone health apps have attracted considerable interest from patients and health managers as a means of promoting more effective self-management of chronic diseases, which l...
Source: Australian Health Review - Category: Hospital Management Authors: Tags: Aust Health Rev Source Type: research
CONCLUSIONS: The present three cases add further evidence that secukinumab is effective and well tolerated in difficult to treat psoriatic patients with multiple comorbidities, namely HBV, latent TBC infection, and hepatic impairment. PMID: 30403898 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
The objective of this review is to summarize the current knowledge of ncRNAs in the context of cardio-oncology. Furthermore, the therapeutic strategies, as well as the prospective translational applications of these ncRNA molecules to the clinic are also discussed. PMID: 30412441 [PubMed - as supplied by publisher]
Source: American Journal of Physiology. Heart and Circulatory Physiology - Category: Physiology Authors: Tags: Am J Physiol Heart Circ Physiol Source Type: research
Publication date: Available online 7 November 2018Source: JACC: Heart FailureAuthor(s): Daniel J. LenihanCorresponding Author
Source: JACC: Heart Failure - Category: Cardiology Source Type: research
This study sought to determine the prevalence of American Heart Association/American College of Cardiology Foundation (AHA/ACCF) heart failure (HF) Stages after potentially cardiotoxic chemotherapy was initiated.BackgroundFor individuals receiving potentially cardiotoxic chemotherapy, the frequency of transitioning from Stage A to more advanced HF Stages is not well described.MethodsIn 143 Stage A HF patients with breast cancer, lymphoma and leukemia, renal cell carcinoma, or sarcoma prior to and then at 3, 6, and 12 to 24 months after potentially cardiotoxic chemotherapy was initiated, we obtained blinded cardiac mag...
Source: JACC: Heart Failure - Category: Cardiology Source Type: research
Authors: Carlucci P, Trigiani M, Mori PA, Mondoni M, Pinelli V, Casalini AG, Conte EG, Buggio G, Villari L, Marchetti G Abstract Diseases of the pleura and pleural space are common and present a significant contribution to the workload of respiratory physicians, accounting for an annual incidence of more than 1.5 million cases in the US with the majority of cases resulting from congestive heart failure, pneumonia, and cancer 1. Although the radiographic and ultrasonographic detection of pleural abnormalities may be obvious, the determination of a specific diagnosis can often represent a challenge. Since pleural eff...
Source: Panminerva Medica - Category: General Medicine Tags: Panminerva Med Source Type: research
(Wiley) Androgen deprivation therapy was associated with a 72 percent higher risk of heart failure in a study of patients with prostate cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
In conclusion, this study found that androgen deprivation therapy users had a higher risk of heart failure than nonusers among prostate cancer patients in both the full cohort study and the propensity score-matched study. PMID: 30402905 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: J Clin Pharmacol Source Type: research
Authors: Cao RY, Li J, Dai Q, Li Q, Yang J Abstract Muscle atrophy is the loss of muscle mass and strength, and it occurs in many diseases, such as cancer, AIDS (acquired immunodeficiency syndrome), congestive heart failure, COPD (chronic obstructive pulmonary disease), renal failure, and severe burns. Muscle atrophy accompanied by cachexia worsens patient's life quality and increases morbidity and mortality. To date there is no effective treatment on that. Here we summarize the diagnosis methods and cellular mechanisms of muscle atrophy. We also discuss the current strategies in muscle atrophy treatment and highli...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
More News: Austria Health | Bahrain Health | Belgium Health | Bosnia and Herzegovina Health | Bulgaria Health | Canada Health | Cancer | Cancer & Oncology | Cardiology | Chemistry | China Health | Croatia Health | Diovan | European Medicines Agency (EMA) | Finland Health | Fish | France Health | Germany Health | Greece Health | Health | Heart | Heart Failure | Hungary Health | International Medicine & Public Health | Ireland Health | Italy Health | Lithuania Health | Liver | Malta Health | Middle East Health | Netherlands Health | Norway Health | Organic | Pharmaceuticals | Poland Health | Portugal Health | Respiratory Medicine | Spain Health | Sports Medicine | Study | Sweden Health | Toxicology | Urology & Nephrology | USA Health